SINTX Technologies Divests Subsidiary to Focus on Medical Device Innovations
SINTX Technologies, Inc. (NASDAQ: SINT), a leader in advanced ceramics for medical applications, has announced the sale of its wholly-owned subsidiary, Technology Assessment and Transfer (TA&T), to Tethon Corporation DBA Tethon 3D (Tethon). This strategic transaction marks a significant step in SINTX’s ongoing transformation, enabling the company to focus on high-growth opportunities in the medical device sector while improving its financial position and operational efficiency.
The divestment aligns with SINTX’s refined strategy to accelerate innovation in healthcare technologies. By streamlining its operations, the company will concentrate on commercializing bioceramic technologies that have the potential to improve patient outcomes and enhance medical implants and devices. The sale of TA&T is expected to reduce corporate liabilities by $750,000 and lower annual operating expenses by more than $1.7 million.
“This sale represents an important milestone in our strategic realignment,” said Eric K. Olson, CEO of SINTX Technologies. “By divesting these assets, we are committing our resources to the medical device market, where our expertise in advanced ceramics can have the greatest impact. This transaction enhances our financial flexibility and supports our efforts to accelerate product development and commercialization in healthcare.”
SINTX remains dedicated to advancing its proprietary silicon nitride-based technologies, which have been used in human implants since 2008. This renewed focus on healthcare innovation underscores the company’s confidence in its core technologies and their potential to drive long-term value creation.
For more information about SINTX Technologies and its materials platform, visit www.sintx.com.
